Unlocking LIpid Biology.
Building Precision MEdicines.
Lime Therapeutics is the lipid medicines company.
Lime Therapeutics is a fast‑growing biotechnology company focused on making a meaningful difference for patients and their families. We are creating new medicines for people with many forms of cancer, cardiometabolic diseases, lysosomal storage diseases, and neurodegenerative disorders, aiming to turn today’s most challenging conditions into manageable and ultimately curable diseases.
Leadership
Team
_edited.jpg)
Scientific and Chemistry Advisory Board
Matthew
Vander Heiden, MD, PhD
Massachusetts Institute of Technology (MIT)
Robert Schwartz, MD, PhD
Weill Cornell Medicine
Rushika Perera, PhD
University of California,
San Francisco
Tuomas Tammela, MD, PhD
Memorial Sloan Kettering Cancer Center
Xuejun Jiang, PhD
Memorial Sloan Kettering Cancer Center
Francis Tavares, PhD
ChemoGenics BioPharma
Business Advisors
Jeff Hatfield, MBA
Ex-CEO, Vividion (acq: Bayer) and Vitae (acq: Allergan)
Ashley Zehnder, DVM, PhD
Co-Founder and CEO, Fauna Bio
Technology
Creating Lipid-Altering Therapeutics
Lipid dysfunction is a hallmark of a broad range of diseases such as cancer, metabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. Despite this, efforts to hunt for lipid-mediated targets and create novel therapies have remained elusive due to lack of technology.
We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a high-throughput screening format, and in live animals.
We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in metabolic diseases and neurodegenerative disorders.
​
Ultimately, we are exploring therapeutic opportunities to touch the lives of 100 million patients.
Publications
A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.
Prakrit V. Jena, Daniel Roxbury, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707631/
​
An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.
Thomas V. Galassi, Prakrit V. Jena, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543545/
​
Long-term in vivo biocompatibility of single-walled carbon nanotubes
Thomas V. Galassi, et. al., and Daniel Heller
News and Events
January 4, 2026
Lime Therapeutics presents at Biotech Showcase as part of JPMorgan Healthcare Conference
December 14, 2025
Lime Therapeutics attends NewYorkBIO Annual Holiday Gathering at New York Stock Exchange
October 17, 2025
CTO Prakrit Jena invited to speak to Cornell University entrepreneurs
September 30, 2025
Lime Therapeutics attends NewYork BIO Innovation Summit
July 30, 2025
CEO Shardule Shah invited to speak on Twinning Strategy Podcast
July 10, 2025
Lime Therapeutics moves into new headquarters at Ford Center Incubator in The Rockefeller University
Our Supporters
Thank you to those supporting our efforts to develop life-changing therapeutics (partial list):
_edited.png)
_edited.png)
Case Western Reserve University
Alumni Venture Fund
Little Green Bamboo
Invest together. Grow together.
Kent Johnson, MBA
Former CFO, BioLegend
Inaki Berenguer, PhD, MBA
Life Extension Ventures
Careers
We do not have any openings at the moment.